- Home
- WASH vs GYRE Comparison
WASH vs GYRE Comparison
Compare WASH & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WASH | GYRE |
|---|---|---|
| Founded | 1800 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 682.2M | 679.4M |
| IPO Year | 1994 | 2004 |
Fundamental Metrics
Financial Performance| Metric | WASH | GYRE |
|---|---|---|
| Price | $32.45 | $7.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $30.25 | $17.00 |
| AVG Volume (30 Days) | ★ 214.1K | 50.7K |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.22% | N/A |
| EPS Growth | ★ 266.26 | N/A |
| EPS | ★ 0.66 | 0.02 |
| Revenue | ★ $229,048,000.00 | $275,000.00 |
| Revenue This Year | N/A | $19.88 |
| Revenue Next Year | $6.19 | N/A |
| P/E Ratio | ★ $11.87 | $354.50 |
| Revenue Growth | ★ 127.57 | N/A |
| 52 Week Low | $25.23 | $6.58 |
| 52 Week High | $37.08 | $11.77 |
Technical Indicators
Market Signals| Indicator | WASH | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 47.05 |
| Support Level | $31.51 | $7.37 |
| Resistance Level | $33.63 | $8.28 |
| Average True Range (ATR) | 1.03 | 0.35 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 81.04 | 36.15 |
Price Performance
Historical ComparisonAbout WASH Washington Trust Bancorp Inc.
Washington Trust Bancorp Inc through its subsidiaries offers banking and financial services to individuals and businesses. It offers a full range of financial services, including commercial banking, mortgage banking, personal banking, and wealth management and trust services, through its offices located in Rhode Island, Connecticut, and Massachusetts. It operates in two segments. The Commercial Banking segment includes lending activities, commercial loans, residential real estate loan deposit activities, and others. The Wealth Management Services segment consists of investment management, financial planning, personal trust, and estate services including services as trustee, personal representative, custodian and guardian, and settlement of decedents' estates.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.